Already an active player in what has been a robust health care M&A market lately, Canadian health care company Valeant Pharmaceuticals International Inc. closed out the Labor Day weekend Monday by announcing its latest acquisition: a $2.6 billion deal for skin care company Medicis Pharmaceutical Corporation.
The New York Times notes that should it close, the Medicis deal will be the 11th acquisition that Mississauga, Ontario–based Valeant has announced in 2012. The company’s other deals this year include March’s $180 million acquisition of Russian cold remedy company Natur Produkt.
